Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2011-04-19
2011-04-19
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C554S001000
Reexamination Certificate
active
07928143
ABSTRACT:
The invention relates to a neurodegenerative disease treating agent for parenteral use, which comprises (2R)-2-propyloctanoic acid or a salt thereof.Since the neurodegenerative disease treating agent of the present invention comprising (2R)-2-propyloctanoic acid or a salt thereof, characterized in that a dosage exceeding about 100 mg per dose is parenterally administered, shows neuropathy improving effect and S-100β increase inhibiting effect in patients with cerebral infarction, it is useful for the treatment of neurodegenerative diseases including cerebral infarction. In addition, it is also useful as a neural regeneration agent after transplantation.
REFERENCES:
patent: 5693636 (1997-12-01), Bondinell et al.
patent: 6608221 (2003-08-01), Toda et al.
patent: 0 632 008 (1995-01-01), None
patent: 1 174 131 (2002-01-01), None
patent: WO 03/007992 (2003-01-01), None
Weinreb, R. N. “Glaucoma neuroprotection: What is it? Why is it needed?” Can J Ophthalmol, 2007, vol. 42, No. 3, pp. 396-398.
Tateishi et al.“Astrocytic Activation and Delayed Infarct Expansion After Permanent Focal Ischemia in Rats. Part II: Suppression of Astrocytic Activation by a Novel Agent (R)-(−)-2-propyloctanoic acid (ONO-2506) Leads to Mitigation of Delayed Infarct Expansion . . . ”,Journal of Cerebral Blood Flow & Metabolism, Jun. 2002, vol. 22, No. 6, pp. 723-734.
Honjo K et. al. “Effects of ONO-2506 Combined With Thrombolytic Therapy in a Rat Model of Thrombotic Focal Cerebral Ischemia” vol. 27, No. 2. Nov. 10, 2001, p. 2301.
Asano T. et. al : “Arundic Acid (ONO-2506) Ameliorates Delayed Ischemic Brain Damage Be Preventing Astrocytic Overproduction of S100B” Current Drug Targets. CNS & Neurological Disorders, Bentham Science Publishers, Hilversum, NL, vol. 4, No. 2, Apr. 1, 2005, p. 127-142.
For the Arundic Acid (ONO-2506) Stroke Study Group et. al. “Safety and Tolerability of Arundic Acid in Acute Ischemic Stroke” Journal of Neurological Sciences, Elsevier Scientific Publishing Co, Amsterdam, NL, vol. 251, No. 1-2, Dec. 21, 2006, pp. 50-56.
European Supplementary Search Report issued in application No. 04773691.3-2123 dated Jan. 12, 2010.
Funakoshi Yosuke
Mizushima Ken
Takakuwa Toshio
Carter Kendra D
Ono Pharmaceutical Co. Ltd.
Padmanabhan Sreeni
Sughrue & Mion, PLLC
LandOfFree
Method for preventing and/or treating neurodegenerative... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for preventing and/or treating neurodegenerative..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for preventing and/or treating neurodegenerative... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2630365